Skip to main content
EHC logo

Encompass Health Corporation (EHC) Stock: Price, Forecast & Analyst Target

Encompass Health Corporation (EHC) — MoonshotScore 81/100 (Exceptional band), calculated Nov 18, 2026. Price $132.25 (-1.98%), as of the Nov 19, 2026 trading session; market cap $13.0B.

Educational signal · not a buy or sell recommendation · How to read this

$132.25 −$2.67 (-1.98%) Market Cap $13.0B

Encompass Health Corporation · EHC · NYSE · Healthcare · Medical - Care Facilities

Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Encompass Health is primarily an inpatient rehabilitation operator, treating patients recovering from strokes, neurological conditions, major injuries, complex orthopedic problems and amputations. The case depends on whether sustained growth in rehabilitation revenue and cash generation can keep outrunning hospital investment, ramp-up costs and a debt load that substantially exceeds cash.

Price as of Nov 19, 2026

Key Statistics

81 of 100

MoonshotScore v2 · Encompass Health (EHC)

Exceptional
Business Quality Elite (85)
Financial Safety Strained (39)
Valuation Fair (60)
Growth Durability Compounding (88)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth, but a strained balance sheet; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.

  • quarterly revenue $1.61B (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 8 of the last 8 reports
  • Altman Z 3.72 · Piotroski F 5

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for EHC (57 recorded, newest six shown)
RecordedScoreBand
81Exceptional
82Exceptional
82Exceptional
82Exceptional
81Exceptional
81Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$132.25
Change on the day-1.98%
52-week range$92.77–$143.90
Market capitalisation$13.0B—
Price / earnings (trailing)21.28
Shares traded on the day946.4K
Beta (volatility vs the S&P 500)0.6

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $95, high $141, latest $132. $141 $95 high $141 Oct 17, 2025 Nov 19, 2026 · $132 $125Oct 17, 2025$114Oct 31, 2025$113Nov 14, 2025$116Nov 28, 2025$107Dec 12, 2025$108Dec 26, 2025$103Jan 9, 2026$98Jan 23, 2026$105Feb 6, 2026$107Feb 20, 2026$107Mar 6, 2026$96Mar 20, 2026$97Apr 2, 2026$106Apr 17, 2026$107May 1, 2026$107May 15, 2026$106May 29, 2026$101Jun 12, 2026$101Jun 26, 2026$110Jul 10, 2026$113Jul 24, 2026$125Aug 7, 2026$120Aug 21, 2026$122Sep 4, 2026$122Sep 18, 2026$120Oct 2, 2026$128Oct 16, 2026$136Oct 30, 2026$141Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Encompass Health (EHC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Weak
Valuation Moderate
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Moderate
Debt/Equity Negative
ROE Strong
Gross Margin Neutral

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Encompass Health (EHC), and what does it report?

Short answer · as of

Encompass Health provides focused recovery care after serious illness or injury, including therapy delivered in rehabilitation hospitals.

Its economic unit is the patient rehabilitation episode: revenue depends mainly on how much inpatient care it delivers and the revenue attached to that care.

This is not a broad acute-care hospital story. Although the business description also covers home health and hospice services, current segment reporting assigns virtually all revenue to Inpatient and only a small residual to Other, making the reported results chiefly a measure of rehabilitation-hospital activity.

2 · Latest results

What do the latest results show for Encompass Health (EHC)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $1.61B.

Revenue extended its upward progression in the latest reported period, but operating profit and net income retreated from the preceding peak. Even with that pullback, revenue and earnings both cleared market expectations, continuing a run in which earnings have repeatedly exceeded estimates.

Management raised its full-year outlook again and explicitly linked the revision primarily to the latest performance. The statements support confidence in the reported momentum, but they do not identify a detailed operating cause, so revenue growth and profit conversion remain the cleaner evidence.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$1.61B$150M$1.50 (diluted)
Q2 FY2026$1.60B$154M$1.54 (diluted)
Q1 FY2026$1.59B$195M$1.93 (diluted)
Q4 FY2025$1.54B$146M$1.43 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Encompass Health (EHC)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow has remained positive throughout the reported series and has exceeded capital spending in each period shown. That consistency is a meaningful strength for a hospital operator funding expansion, although heavier recent capital spending leaves less cash after investment.

Debt substantially outweighs cash, the net cash position is deeply negative and the cash balance has declined across the reported window despite marked swings between periods. Liquidity ratios indicate near-term coverage, and the quality screens are favorable, but continued capital intensity and preopening costs could tighten financial flexibility if rehabilitation revenue or margins weaken.

The dividend has been raised from its recent level while the company continues to invest. That makes cash remaining after capital spending, distributions and ramp-up costs more informative than the headline cash balance alone.

4 · What to check next?

What should you watch next at Encompass Health (EHC)?

Short answer · as of

Current published price targets run low $150.00 · high $165.00 · consensus $154.86 · median $155.00 against a quoted price of $132.25 (as of Nov 19, 2026).

The upcoming earnings release needs to preserve the upward revenue pattern while showing whether operating profit can recover from its latest sequential decline. Another revenue and earnings beat would reinforce recent execution; weaker profit conversion despite higher revenue would point to cost pressure inside the rehabilitation platform.

Cash deserves equal attention. Watch operating cash flow after capital spending, any rebuilding of the cash balance against debt, and whether preopening and ramp-up costs remain aligned with management’s stated outlook as hospital investment continues.

Longer-range analyst estimates assume continued expansion in revenue and earnings. Progress toward that path requires more than topline growth: the rehabilitation business must retain enough operating profit and cash after investment to support leverage and shareholder distributions.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Encompass Health compare with its peers?

Short answer

Encompass Health's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Encompass Health differs from diversified hospital and post-acute groups because current reported revenue is concentrated overwhelmingly in inpatient rehabilitation. Comparisons based on a blended mix of acute hospitals, home care and hospice can therefore miss the company’s direct exposure to rehabilitation-hospital performance.

That concentration offers a clearer operating profile, but it also limits diversification across service lines. The combination of sustained revenue growth, healthy operating profitability, substantial capital spending and meaningful leverage makes cash conversion a more revealing comparison point than revenue scale alone.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Tenet Healthcare Corporation (THC) Same industry, near in market value$271.34 Nov 18, 2026$21.6B94 5-pillar Nov 18, 2026
LifeStance Health Group, Inc. (LFST) Same industry, near in market value$13.77 Nov 18, 2026$5.24B92 5-pillar Nov 18, 2026
Universal Health Services, Inc. (UHS) Same industry, near in market value$186.07 Nov 18, 2026$10.7B91 5-pillar Nov 18, 2026
Chemed Corporation (CHE) Same industry, near in market value$546.72 Nov 18, 2026$7.09B85 5-pillar Nov 18, 2026
Option Care Health, Inc. (OPCH) Same industry, near in market value$31.71 Nov 18, 2026$4.75B85 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Named competitor$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Encompass Health (EHC) — this page$132.25$13.0B81
Fresenius Medical Care AG & Co. KGaA (FMS) Named competitor$20.95 Nov 18, 2026$10.9B80 5-pillar Nov 18, 2026
Dr. Reddy's Laboratories Limited (RDY) Named competitor$14.85 Nov 19, 2026$12.4B77 5-pillar Nov 18, 2026
DaVita Inc. (DVA) Same industry, near in market value$156.24 Nov 19, 2026$9.83B76 5-pillar Nov 18, 2026
National HealthCare Corporation (NHC) Same industry, near in market value$201.60 Nov 18, 2026$3.16B76 5-pillar Nov 18, 2026
The Ensign Group, Inc. (ENSG) Named competitor$176.59 Nov 19, 2026$10.3B74 5-pillar Nov 18, 2026
Solventum Corporation (SOLV) Named competitor$86.48 Nov 18, 2026$14.7B66 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$150.00 – $165.00
Consensus target
$154.86
Median target
$155.00

Consensus record · Captured .

Measured against a quoted price of $132.25 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 19, 2026

Transactions
30
Identified insiders
13
Purchases
0
Sales
6
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held EHC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported EHC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Encompass Health (EHC)?

Read these with our analysis →

Common Questions About EHC (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What care does Encompass Health provide after a stroke or spinal injury?

Encompass Health provides focused inpatient or outpatient rehabilitation for patients recovering from strokes, neurological disorders, brain or spinal injuries and other complex conditions. Therapy and recovery care, rather than general acute treatment, define the core offering.

How concentrated is Encompass Health in inpatient rehabilitation?

Current segment reporting assigns virtually all revenue to Inpatient, with only a small amount recorded as Other. Companywide results therefore track the rehabilitation-hospital business far more closely than a broadly diversified post-acute portfolio.

Why do preopening and ramp-up costs matter for Encompass Health?

Management expects these costs to continue as facilities prepare to open and build activity. They absorb profit and cash before a new hospital reaches a steadier operating level, so their relationship to revenue growth is an important test of expansion economics.

Is Encompass Health converting rehabilitation earnings into cash after capital spending?

Operating cash flow has exceeded capital spending in each reported period, leaving a positive surplus after investment. The remaining constraint is balance-sheet capacity: debt is far larger than cash, and the cash balance has declined across the reported window.

What is the EHC stock price today?

The last price recorded for Encompass Health Corporation (EHC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the EHC price target?

The analyst consensus price target for Encompass Health Corporation (EHC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Encompass Health (EHC), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Encompass Health (EHC)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for Encompass Health (EHC)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Management outlook — dated call excerpts; Next scheduled dividend; Recent dividends paid
  • 4. What should you watch next at Encompass Health (EHC)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Management outlook — dated call excerpts; Next scheduled dividend
  • 5. How does Encompass Health compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Cash, investments and debt
  • FAQ: What care does Encompass Health provide after a stroke or spinal injury?: Business description; Revenue by segment
  • FAQ: How concentrated is Encompass Health in inpatient rehabilitation?: Revenue by segment; Business description; Annual revenue and net result (USD millions)
  • FAQ: Why do preopening and ramp-up costs matter for Encompass Health?: Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands)
  • FAQ: Is Encompass Health converting rehabilitation earnings into cash after capital spending?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.